Cargando…

Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer

Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essentia...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Fernanda Cardoso, Brandão, Douglas Cardoso, Ferreira, Everton Allan, Siqueira, Raoni Pais, Ferreira, Helen Soares Valença, Da Silva Filho, Ademar Alves, Araújo, Thaise Gonçalves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610388/
https://www.ncbi.nlm.nih.gov/pubmed/37895937
http://dx.doi.org/10.3390/ph16101466
_version_ 1785128242921865216
author da Silva, Fernanda Cardoso
Brandão, Douglas Cardoso
Ferreira, Everton Allan
Siqueira, Raoni Pais
Ferreira, Helen Soares Valença
Da Silva Filho, Ademar Alves
Araújo, Thaise Gonçalves
author_facet da Silva, Fernanda Cardoso
Brandão, Douglas Cardoso
Ferreira, Everton Allan
Siqueira, Raoni Pais
Ferreira, Helen Soares Valença
Da Silva Filho, Ademar Alves
Araújo, Thaise Gonçalves
author_sort da Silva, Fernanda Cardoso
collection PubMed
description Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies.
format Online
Article
Text
id pubmed-10610388
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106103882023-10-28 Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer da Silva, Fernanda Cardoso Brandão, Douglas Cardoso Ferreira, Everton Allan Siqueira, Raoni Pais Ferreira, Helen Soares Valença Da Silva Filho, Ademar Alves Araújo, Thaise Gonçalves Pharmaceuticals (Basel) Review Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies. MDPI 2023-10-16 /pmc/articles/PMC10610388/ /pubmed/37895937 http://dx.doi.org/10.3390/ph16101466 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
da Silva, Fernanda Cardoso
Brandão, Douglas Cardoso
Ferreira, Everton Allan
Siqueira, Raoni Pais
Ferreira, Helen Soares Valença
Da Silva Filho, Ademar Alves
Araújo, Thaise Gonçalves
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
title Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
title_full Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
title_fullStr Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
title_full_unstemmed Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
title_short Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
title_sort tailoring potential natural compounds for the treatment of luminal breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610388/
https://www.ncbi.nlm.nih.gov/pubmed/37895937
http://dx.doi.org/10.3390/ph16101466
work_keys_str_mv AT dasilvafernandacardoso tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer
AT brandaodouglascardoso tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer
AT ferreiraevertonallan tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer
AT siqueiraraonipais tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer
AT ferreirahelensoaresvalenca tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer
AT dasilvafilhoademaralves tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer
AT araujothaisegoncalves tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer